Abstract:Atherosclerosis (AS) is a prevalent cardiovascular disease with severe morbidity and high mortality. Phenotypic regulation of vascular smooth muscle cells (VSMCs) from the contractile and quiescent phenotype to the synthetic type is a critical step for the vascular remodeling of AS. Atorvastatin, as a 3‑hydroxy‑3‑methyl‑glutaryl coenzyme A reductase inhibitor, presents an anti‑inflammatory effect to improve vascular endothelial functions. The aim of the present study was to examine the effect of atorvastatin on VSMCs phenotypic transformation and the underlying mechanism. The rat primary VSMCs were isolated and identified. The protein expression of contractile proteins, such as α‑SMA, SM‑MHC, and SM22α, was reduced by angiotensin II (AngII) and enhanced by atorvastatin, in which atorvastatin could reverse the effect of AngII in the VSMCs. The treatment of HDAC inhibitor trichostatin A was able to enhance AngII‑inhibited expression of α‑SMA and SM‑MHC. Atorvastatin regulated AngII‑associated VSMCs phenotypic transformation by epigenetically regulating contractile proteins. Moreover, atorvastatin modulated platelet‑derived growth factor‑BB (PDGF‑BB)‑induced VSMC phenotypic transformation by modulating the Akt/forkhead Box O4 (FOXO4) axis. Immunofluorescence analysis revealed that PDGF‑BB enhanced the accumulation of FOXO4 in the VSMCs, while the treatment of atorvastatin was able to attenuate this effect and the co‑treatment of Akt inhibitor LY294002 could further inhibit the phenotype. The treatment of PDGF‑BB enhanced the interaction of SRF with FOXO4 and myocardin in the VSMCs, in which the co‑treatment of atorvastatin and LY294002 could reverse the effect of PDGF‑BB in the system. Thus, atorvastatin regulates VSMCs phenotypic transformation by epigenetically modulating contractile proteins and mediating the Akt/FOXO4 axis. Findings of the present study provide new insights into the mechanism by which atorvastatin modulates VSMCs, providing valuable evidence for the application of atorvastatin in the treatment of AS.

Atorvastatin Calcium Inhibits PDGF-ββ-Induced Proliferation and Migration of VSMCs Through the G0/G1 Cell Cycle Arrest and Suppression of Activated PDGFRβ-PI3K-Akt Signaling Cascade

Atorvastatin enhances endothelial cell function in posttransplant poor graft function.

Influence of atorvastatin on ion pump activity of smooth muscle cells and intima proliferation after arterial intimal injury

Atorvastatin Reduces Accumulation of Vascular Smooth Muscle Cells to Inhibit Intimal Hyperplasia Via P38 MAPK Pathway Inhibition in a Rat Model of Vein Graft.

Simvastatin inhibit proliferation in vascular smooth muscle cells in association with induction of PTEN and p27

Pgc-1 Alpha Inhibits Oleic Acid Induced Proliferation And Migration Of Rat Vascular Smooth Muscle Cells

Effects of Atrovastatin on the Proliferation Function of EPCs Isolated from CHD Patients and Related Mechanisms on PI3/Akt and ERK Pathway

Atorvastatin regulates vascular smooth muscle cell phenotypic transformation by epigenetically modulating contractile proteins and mediating Akt/FOXO4 axis

The Effect of Atorvastatin on Migration of Rat Vascular Smooth Muscle Cell and Expression of Cathepsin S

Atorvastatin Treatment Modulates P16 Promoter Methylation to Regulate P16 Expression

Atorvastatin Attenuates Homocysteine-Induced Migration of Smooth Muscle Cells Through Mevalonate Pathway Involving Reactive Oxygen Species and P38 MAPK.

The ADP Antagonist MRS2179 Regulates the Phenotype of Smooth Muscle Cells to Limit Intimal Hyperplasia

Effects of Simvastatin on Reorganization of Focal Adhesion and Actin Cytoskeleton in Vascular Smooth Muscle Cells Induced by Platelet-Derived Growth Factor-BB

Ppar Gamma Inhibits Vsmc Proliferation And Migration Via Attenuating Oxidative Stress Through Upregulating Ucp2

Atorvastatin Prevents Glomerular Extracellular Matrix Formation by Interfering with the PKC Signaling Pathway.

Transforming Growth Factor β Inhibits Platelet Derived Growth Factor-Induced Vascular Smooth Muscle Cell Proliferation via Akt-Independent, Smad-Mediated Cyclin D1 Downregulation

Atorvastatin Reduces Vascular Endothelial Growth Factor (VEGF) Expression in Human Non-Small Cell Lung Carcinomas (nsclcs) Via Inhibition of Reactive Oxygen Species (ROS) Production

Effect of Atorvastatin on High Concentration Glucose Induced Aldose Reductase, NF-κB Expression and Proliferation of Vascular Smooth Muscle Cells

Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins

Effect of Atorvastatin on Myocyte Enhancer Factor 2A Gene Mutational Vascular Smooth Muscle Cells

Impact of ERK2 signaling pathway blockade on platelet-derived growth factor-induced vascular smooth muscle cells proliferation,migration and transform growth factar-β1 expression